Your browser doesn't support javascript.
Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory?
Paar, Vera; Wernly, Bernhard; Zhou, Zhichao; Motloch, Lukas J; Hoppe, Uta C; Egle, Alexander; Lichtenauer, Michael.
  • Paar V; Department of Internal Medicine II, Division of Cardiology, Paracelsus Medical University of Salzburg, Salzburg, Austria.
  • Wernly B; Department of Internal Medicine II, Division of Cardiology, Paracelsus Medical University of Salzburg, Salzburg, Austria.
  • Zhou Z; Department of Medicine, Division of Cardiology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Motloch LJ; Department of Internal Medicine II, Division of Cardiology, Paracelsus Medical University of Salzburg, Salzburg, Austria.
  • Hoppe UC; Department of Internal Medicine II, Division of Cardiology, Paracelsus Medical University of Salzburg, Salzburg, Austria.
  • Egle A; Department of Internal Medicine III, Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University of Salzburg, Salzburg, Austria.
  • Lichtenauer M; Department of Internal Medicine II, Division of Cardiology, Paracelsus Medical University of Salzburg, Salzburg, Austria. m.lichtenauer@salk.at.
J Thromb Thrombolysis ; 51(1): 226-231, 2021 Jan.
Article in English | MEDLINE | ID: covidwho-648995
ABSTRACT
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been linked to a higher risk of mortality compared to influenza, which is mainly due to severe secondary diseases, such as acute respiratory distress syndrome (ARDS). In turn, ARDS is characterized by an acute inflammation and an excessive activity of the coagulation cascade, rising the vulnerability for venous thromboembolic events. In order to investigate the relation of inflammation and the influence of coagulation factors on their release, human peripheral mononuclear blood cells (PBMCs) were treated with autologous serum, heparinized plasma and different doses of fibrin. Thereafter, the concentration of pro-inflammatory cytokines and chemokines in the secretome of PBMCs was measured by enzyme-linked immunosorbent assay. Our analyses revealed autologous serum to significantly increase the secretion of cytokines and chemokines after 24 h of incubation time. Furthermore, the addition of fibrin markedly increased the secretion of cytokines and chemokines by PBMCs in a dose-dependent manner. Consequently, in accordance with previous studies, our study outlines that anti-coagulation may constitute a promising tool for the treatment of SARS-CoV-2, reducing both, the cytokine storm, as well as the risk for thrombotic complications.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Blood Coagulation / Fibrin / Cytokine Release Syndrome / COVID-19 / Inflammation Type of study: Prognostic study Limits: Humans Language: English Journal: J Thromb Thrombolysis Journal subject: Vascular Diseases Year: 2021 Document Type: Article Affiliation country: S11239-020-02212-6

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Blood Coagulation / Fibrin / Cytokine Release Syndrome / COVID-19 / Inflammation Type of study: Prognostic study Limits: Humans Language: English Journal: J Thromb Thrombolysis Journal subject: Vascular Diseases Year: 2021 Document Type: Article Affiliation country: S11239-020-02212-6